3[3]Juergens C,Fernandes C,Hashe E,et al.Electrocardiographic measurement of infarct size after thrombolytic therapy[J].J Am Coll Cardial,1996,27 (3):617～624.
4[5]Pachai A,Erlendsson AK,Brandslund I.Streptokinaes,complement activation and hypotension[J].APMIS,1997,105 (8):650～654.
5Briguori C,Sarais C,Pagnotta P,et al.Elective versus provisional intra-aortic balloon pumping in high-risk percutaneous transluminal coronary angioplasty[J].Am Heart J,2003,145(4):700-707.
6Piana RN,Paik G Y,Moscucci M,et al.Incidence and treatment of"Ino-reflow"after percutaneous coronary intervention[J].Circulation,1994,89(6):2 514-2 518.
7Morishima I,Sone T,Mokuno S,et al.Clinical significance of no reflow phenomenon oberserved onangiography after successful treatment of acute myocardial infarction with percutaneous transluminal coronary angioplasty[J].Am Heart J,1995,130(2):239-243.
8Kloner RA,Ganote CE,Jennings RB.The"no-reflow"phenomenon after temporary coronary occlusion in the dog[J].J Clin Invest,1974,54(6):1 496-1 508.
9Genda S,Miura T,Miki T,et al.K (ATP) channel opening is a endogenous mechanism of protection against the no reflow phenomenon but its function is compromised by hypercholesterolemia[J].J Am CollCardiol,2002,40(7):1 339-1 346.
10De Lemos JA,Antman EM,Gibson CM,et al.Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction:Observate for the TIMI 14 trial[J].Circulation,2000,101(3):239-243.
